FDA Cites R3 Medical Companies in 2026-08-14 Warning Letter — Unapproved New Drugs/Unlicensed Biological Product Violations
Letter issued · posted to fda.gov .
Subject as published: Unapproved New Drugs/Unlicensed Biological Product Violations
TL;DR
The FDA's Center for Biologics Evaluation and Research (CBER) issued a Warning Letter to R3 Medical Companies on August 14, 2026 (Reference CBER 26-726330), following inspections conducted November 17–December 16, 2025, at facilities in Scottsdale, Arizona. The letter states that four umbilical cord-derived products (ReBellaWJ, ReBellaXO, ReBellaXOL, and ReBellaCB) are unapproved new drugs in violation of FD&C Act section 505(a) and unlicensed biological products in violation of PHS Act section 351(a)(1), based on marketing claims across social media and websites indicating use for treating conditions including arthritis, diabetes, erectile dysfunction, autism, and organ failure. The letter also cites significant current good manufacturing practice (CGMP) violations under FD&C Act section 501(a)(2)(B) and 21 CFR parts 210 and 211, rendering the products adulterated.
Argus analysis
# FDA Warning Letter Analysis: R3 Medical Companies
**Company and Violations**
The FDA's Center for Biologics Evaluation and Research (CBER) issued a Warning Letter to R3 Medical Companies on August 14, 2026, following inspections of co-located facilities Bello Bio, LLC and Regen Suppliers, LLC in Scottsdale, Arizona (November–December 2025). The inspection found that these entities manufacture, label, and distribute four umbilical cord-derived products: ReBellaWJ, ReBellaXO, ReBellaXOL, and ReBellaCB. The FDA documented marketing claims across YouTube, TikTok, Instagram, Facebook, and company websites indicating these products treat or prevent disease conditions including arthritis, neurological disorders, autism, diabetes, and erectile dysfunction.
**Regulatory Citations and Meaning**
The Warning Letter cites violations of section 505(a) of the Federal Food, Drug, and Cosmetic Act (unapproved new drugs) and section 351(a)(1) of the Public Health Service Act (unlicensed biological products). The FDA also documented current good manufacturing practice (CGMP) violations under 21 CFR parts 210 and 211, meaning manufacturing controls, facilities, and processes do not meet federal standards. Additionally, the products fail to qualify as human cells, tissues, or cellular or tissue-based products (HCT/Ps) under 21 CFR 1271.10(a)—specifically, they do not meet the "homologous use only" requirement, meaning their intended function extends beyond the donor tissue's original function.
**Timeline and Industry Monitoring**
The Warning Letter does not specify a response deadline within the document. Compliance officers monitoring similar regenerative medicine companies should expect follow-up correspondence from CBER regarding corrective actions. Industry observers will likely track whether R3 Medical discontinues product distribution, initiates regulatory submissions (premarket approval or biologics license applications), or faces enforcement actions including seizure or injunction. The specificity of FDA's social media documentation suggests increased scrutiny of digital marketing claims in the regenerative medicine sector.
Severity context
Critical severity. Typically reserved for data integrity, sterile-product CGMP, or repeat violations — matters that historically precede injunctions, consent decrees, or import alerts.
Regulatory background
Unapproved-drug letters cite 21 USC 355 (NDA requirement) or 21 USC 331(d) (introduction into interstate commerce). FDA increasingly applies these provisions to homeopathic products, kratom, and certain compounded preparations.
What peer compliance teams typically do next
Most compliance officers at peer companies use a Warning Letter against a named entity as a checklist for their own CAPA program. Common steps: pull the verbatim FDA letter; map each cited 21 CFR section against the team’s SOP library; confirm CAPA coverage; brief the QMR (Quality Management Review) on whether the cited subject matter is in scope for the next internal audit. The 15-business-day response window applies to the cited entity, not to peers — but a documented internal review against the cited subjects is what regulators expect to see if a peer is later inspected on the same topic.
Excerpt from the FDA Warning Letter (public domain, 17 USC §105)
WARNING LETTER R3 Medical Companies MARCS-CMS 726330 — August 14, 2026 More Warning Letters Warning Letters About Warning and Close-Out Letters Delivery Method: Via UPS and EMAIL Reference #: CBER 26-726330 Product: Biologics Recipient: Recipient Name David L. Greene, M.D. Recipient Title Chief Executive Officer R3 Medical Companies 10045 E. Dynamite Blvd., Suite 260 Scottsdale , AZ 85262 United States dgreene@bello.bio dgreene@regensuppliers.com Issuing Office: Center for Biologics Evaluation and Research (CBER) United States WARNING LETTER August 14, 2026 CBER 26-726330 Dear Dr. Greene: The United States Food and Drug Administration (FDA) inspected your facilities, Bello Bio, LLC (herein referred to as “Bello”) and Regen Suppliers, LLC (herein referred to as “Regen”) co-located at 10045 E. Dynamite Blvd., Suite 260, Scottsdale, AZ 85262, between November 17, 2025, and December 16, 2025. 1,2 During the inspections, FDA documented that Bello contract manufactures and labels umbilical cord derived products, ReBellaWJ, ReBellaXO, and ReBellaXOL, for private label distribution by Regen. 3,4 Regen approves, labels, stores, and distributes the aforementioned products as well as an umbilical cord blood derived product, ReBellaCB, contract manufactured under private label by (b)(4) ReBellaWJ, ReBellaXO, and ReBellaXOL will herein be referred to as “your umbilical cord derived products.” These three products, together with ReBellaCB, will be referred to collectively as “your products.” This letter is to advise you that your products are unapproved new drugs in violation of section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. § 355(a). Your products are also unlicensed biological products in violation of section 351(a)(1) of the Public Health Service Act (PHS Act), 42 U.S.C. § 262(a)(1). A biological product for which a biologics license application (BLA) has been approved under section 351(a) of the PHS Act is not required to have an approved application under section 505 of the FD&C Act, 21 U.S.C. § 355; 42 U.S.C. § 262(j). Otherwise, with certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&C Act. Your introduction or delivery for introduction of your products into interstate commerce, or the causing thereof, is prohibited under section 301(d) of the FD&C Act, 21 U.S.C. § 331(d). This warning letter also summarizes significant violations of current good manufacturing practice (CGMP) requirements, including violations of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. § 351(a)(2)(B), and 21 CFR parts 210 and 211, in the manufacture of your products. Because your methods, facilities, or controls for manufacturing, processing, packing, or holding drugs do not conform to CGMP, your products are adulterated within the meaning of section 501(a)(2)(B) of the FD&C Act…
Excerpt only. The full verbatim Warning Letter is the source of truth — always read the original before regulatory decisions.
The verbatim FDA Warning Letter is the source of truth. Always read the original before acting on any analysis or summary on this page.
Read the full letter on fda.gov ↗Frequently asked questions
- What FDA violations was R3 Medical Companies cited for?
- The FDA Warning Letter to R3 Medical Companies (issuing office: Center for Biologics Evaluation and Research (CBER)) cites: Unapproved New Drugs/Unlicensed Biological Product Violations. Classification: Unapproved drug.
- When did FDA issue the warning letter to R3 Medical Companies?
- FDA issued the letter (MARCS-CMS 726330) on 2026-08-14 and posted it publicly on fda.gov on 2026-08-25.
- Is the FDA warning letter to R3 Medical Companies publicly available?
- Yes. The full verbatim letter is published at fda.gov. Argus HQ links directly to the source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/r3-medical-companies-726330-08142026.
- What does a "critical" severity rating mean for this letter?
- Critical severity. Typically reserved for data integrity, sterile-product CGMP, or repeat violations — matters that historically precede injunctions, consent decrees, or import alerts.
argus.hq
Don’t find out about the next one six weeks late.
Argus reads every FDA Warning Letter the day it publishes, summarizes it against your watchlist, and lands the ones touching your business in your inbox at 6am ET. Plans from $99/month. Cancel any time.
methodology
The analysis above is produced by Anthropic Claude Haiku 4.5 against the verbatim FDA Warning Letter excerpt and is brand-voice lint-checked before publish. The TL;DR is the same summary that ships in the customer email digest. Severity is auto-classified by Argus from the subject string and letter body using rules documented in lib/ingestion/fda-warning-letters.ts.
Argus HQ is informational only. Summaries and analyses are AI-generated and may contain errors, misclassifications, or omissions. Verify against the FDA source URL above. Argus HQ is not a law firm, accounting firm, or regulatory agency, and provides no legal, accounting, financial, medical, or regulatory advice.
Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder
Cite this record
Reusing this data in reporting or research? Here’s a ready-made citation.
Argus HQ Research (2026). FDA Cites R3 Medical Companies in 2026-08-14 Warning Letter — Unapproved New Drugs/Unlicensed Biological Product Violations. Digital Empire Holdings LLC. Retrieved from https://argushq.ai/fda/warning-letter/fda-wl-r3-medical-companies-2026-08-14-unapproved-drug
"FDA Cites R3 Medical Companies in 2026-08-14 Warning Letter — Unapproved New Drugs/Unlicensed Biological Product Violations." Argus HQ Research, Digital Empire Holdings LLC, 2026, argushq.ai/fda/warning-letter/fda-wl-r3-medical-companies-2026-08-14-unapproved-drug.
Argus HQ Research. "FDA Cites R3 Medical Companies in 2026-08-14 Warning Letter — Unapproved New Drugs/Unlicensed Biological Product Violations." Digital Empire Holdings LLC. Accessed August 27, 2026. https://argushq.ai/fda/warning-letter/fda-wl-r3-medical-companies-2026-08-14-unapproved-drug.
@misc{argushq_argushq_ai_fda_warning_letter_fda_wl_r3_medical_companies_2026_08_14_unapproved_drug_2026,
title = {FDA Cites R3 Medical Companies in 2026-08-14 Warning Letter — Unapproved New Drugs/Unlicensed Biological Product Violations},
author = {{Argus HQ Research}},
year = {2026},
publisher = {Digital Empire Holdings LLC},
url = {https://argushq.ai/fda/warning-letter/fda-wl-r3-medical-companies-2026-08-14-unapproved-drug},
note = {Accessed: August 27, 2026}
}